Evidence map›Paper›PMID 30297367›Full record

ArticleAntimicrobial agents and chemotherapy2018

Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.

Deepak Kumar Deep, Ruchi Singh, Arpita Kulshrestha, Saima Wajid, Poonam Salotra

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Non-Vesicular Lipid Transport Machinery inInternational journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Deepak Kumar DeepNational Institute of Pathology (ICMR), Safdarjung Hospital Campus, New Delhi, India.
Ruchi SinghNational Institute of Pathology (ICMR), Safdarjung Hospital Campus, New Delhi, India.ORCID 0000-0001-8094-4703
Arpita KulshresthaNational Institute of Pathology (ICMR), Safdarjung Hospital Campus, New Delhi, India.
Saima WajidDepartment of Biotechnology, Faculty of Science, Jamia Hamdard, New Delhi, India.
Poonam SalotraNational Institute of Pathology (ICMR), Safdarjung Hospital Campus, New Delhi, India salotra@vsnl.com.ORCID 0000-0002-4057-4872
Safdarjang Hospital · INJamia Hamdard · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The oral drug miltefosine (MIL) was introduced in the Indian subcontinent in the year 2002 for the treatment of visceral leishmaniasis (VL). However, recent reports on its declining efficacy and increasing relapse rates pose a serious concern. An understanding of the factors contributing to MIL tolerance in

Indexed as

AnimalsAntiprotozoal AgentsCytokinesDrug ResistanceFemaleHost-Pathogen InteractionsInflammationLeishmania donovaniLeishmaniasis, VisceralLipaseMacrophagesMice, Inbred BALB COxidative StressPhosphorylcholineProtozoan ProteinsAntiprotozoal AgentsCytokinesLipasemiltefosinePhosphorylcholineProtozoan ProteinsLeishmania donovanilipase precursormiltefosineoverexpressionparasite persistence

Identifiers

PMID30297367
PMCPMC6256749
OpenAlexW2895003887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.